News
CORT ▼ -1.0% - Corcept Therapeutics Incorporated
CORT ▼ -1.0% - Corcept Therapeutics Incorporated
$CORT Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer
26-OCT-2026 08:03 AM ET
Share this post
More filings for $CORT
CORT ▼ -2.9% - Corcept Therapeutics IncorporatedNov 4, 2026CORT ▼ -3.6% - Corcept Therapeutics IncorporatedNov 3, 2026CORT ▼ -6.3% - Corcept Therapeutics IncorporatedNov 3, 2026CORT - Corcept Therapeutics Incorporated - SEC Filing Update (27-OCT-2026) | ThinkSabio - Stocks SimplifiedOct 27, 2026CORT ▲ +0.3% - Corcept Therapeutics IncorporatedOct 27, 2026CORT ▼ -1.0% - Corcept Therapeutics IncorporatedOct 26, 2026
View full $CORT filing history →💬 Comments
Loading comments…
Leave a comment